



Sabril® (vigabatrin) – First-time generic

- On January 20, 2019, Teva launched an [AB-rated](#) generic version of Lundbeck's [Sabril \(vigabatrin\)](#) tablets.
- Sabril is approved as adjunctive therapy for adults and pediatric patients 10 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss and as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss.
- Sabril is also available generically as a [powder for oral solution](#). The oral solution formulation shares the same indications as the tablets.
- Sabril carries a boxed warning for permanent vision loss.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.